A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Inclusion criteria

• . Participant must be ≥ 12 years of age at the time of signing the informed consent/assent
• . Weight ≥ 35 kg
• . Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility.
• . Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics
• . Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization
• . Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value at screening.
• . Presence of positive (PCR or culture) PsA in an airway sample at least once in the last 24 months prior to screening
• . Presence of culture positive PsA in sputum at least within 5 weeks of randomization. Participants who have previously received PsA eradication therapy, as determined appropriate by their treating provider, but remain colonized with PsA are eligible for the study.

Exclusion criteria